Hematology/Oncology · Hartford, CT
NPI
1013976299
Since 2006
Specialty
Hematology/Oncology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
43 Woodland St, Suite G-80, Gothic Park
Hartford, CT, 06105
Phone (860) 527-5803
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
82,308 services
Medicare patients, 2024
313
Average age 77
Drug cost, 2024
$7.5M
1,662 prescriptions
Company payments, 2025
$43.04
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joel S Silver was code J0897 (injection, denosumab, 1 mg), 4,560 times for 16 patients. In total Joel S Silver billed 82,308 services in 93 codes, and Medicare paid $1.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-11-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 4,560 | 16 | $20.53 | $94K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 4,440 | 11 | $5.83 | $26K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,400 | 16 | $15.64 | $38K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,550 | 14 | $0.09 | $141 |
| 99214 Office E&M - Established | Office | 629 | 235 | $96.98 | $61K |
| 99215 Office E&M - Established | Office | 379 | 95 | $142.38 | $54K |
| 96372 Injection Administration | Office | 302 | 43 | $11.54 | $3,484 |
| 96365 Intravenous Infusion, Hydration | Office | 193 | 43 | $52.11 | $10K |
| 96413 Chemotherapy Administration | Office | 189 | 22 | $103.66 | $20K |
| 96366 Intravenous Infusion, Hydration | Office | 176 | 15 | $16.94 | $2,981 |
| 96367 Intravenous Infusion, Hydration | Office | 144 | 18 | $23.48 | $3,381 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 125 | 14 | $4.84 | $605 |
| 96375 Injection Administration | Office | 121 | 27 | $12.92 | $1,563 |
| 96415 Chemotherapy Administration | Office | 67 | 12 | $23.29 | $1,561 |
| 99232 Hospital E&M - Subsequent | Facility | 60 | 21 | $63.79 | $3,827 |
By year: 2022 $2.2M for 103,789 services; 2023 $1.8M for 90,567 services; 2024 $1.9M for 82,308 services.
Medicare prescription drug claims, 2024
In 2024, the drug Joel S Silver prescribed most often to Medicare patients was Anastrozole, with 84 prescriptions and refills. In total Joel S Silver wrote 1,662 Medicare prescriptions that cost $7.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 84 | 250 | 26 | $1,452 |
| Xarelto Rivaroxaban | 76 | 132 | 18 | $75K |
| Dexamethasone Generic | 65 | 90 | 18 | $1,123 |
| Oxycodone Hcl Generic | 64 | 64 | 16 | $1,139 |
| Eliquis Apixaban | 63 | 123 | 16 | $70K |
| Pomalyst Pomalidomide | 53 | 53 | Under 11 | $1.2M |
| Acyclovir Generic | 52 | 111 | Under 11 | $1,003 |
| Revlimid Lenalidomide | 47 | 47 | Under 11 | $796K |
| Hydroxyurea Generic | 47 | 135 | 15 | $1,213 |
| Prochlorperazine Maleate Generic | 43 | 43 | 26 | $456 |
| Ondansetron Hcl Generic | 42 | 42 | 12 | $1,243 |
| Hydromorphone Hcl Generic | 36 | 36 | Under 11 | $317 |
| Brukinsa Zanubrutinib | 35 | 35 | Under 11 | $611K |
| Lenalidomide Generic | 35 | 35 | Under 11 | $342K |
| Gabapentin Generic | 33 | 59 | 11 | $1,083 |
Brand drugs: - claims; generic drugs: 1,017 claims; opioid claims: 160.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joel S Silver $43.04 ($43.04 in general payments such as food, travel and fees) from 2 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $26.36.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.